Literature DB >> 32087569

Specificity of human natural antibodies referred to as anti-Tn.

Kira Dobrochaeva1, Nailya Khasbiullina2, Nadezhda Shilova3, Nadezhda Antipova4, Polina Obukhova5, Tatiana Ovchinnikova1, Oxana Galanina1, Ola Blixt6, Horst Kunz7, Alexander Filatov8, Yuriy Knirel9, Jacques LePendu10, Sergey Khaidukov1, Nicolai Bovin11.   

Abstract

To understand the role of human natural IgM known as antibodies against the carbohydrate epitope Tn, the antibodies were isolated using GalNAcα-Sepharose affinity chromatography, and their specificity was profiled using microarrays (a glycan array printed with oligosaccharides and bacterial polysaccharides, as well as a glycopeptide array), flow cytometry, and inhibition ELISA. The antibodies bound a restricted number of GalNAcα-terminated oligosaccharides better than the parent monosaccharide, e.g., 6-O-Su-GalNAcα and GalNAcα1-3Galβ1-3(4)GlcNAcβ. The binding with several bacterial polysaccharides that have no structural resemblance to the affinity ligand GalNAcα was quite unexpected. Given that GalNAcα is considered the key fragment of the Tn antigen, it is surprising that these antibodies bind weakly GalNAcα-OSer and do not bind a wide variety of GalNAcα-OSer/Thr-containing mucin glycopeptides. At the same time, we have observed specific binding to cells having Tn-positive glycoproteins containing similar glycopeptide motifs in a conformationally rigid macromolecule. Thus, specific recognition of the Tn antigen apparently requires that the naturally occurring "anti-Tn" IgM recognize a complex epitope comprising the GalNAcα as an essential component and a fairly long amino acid sequence where the amino acids adjacent to GalNAcα do not contact the antibody paratope; i.e., the antibodies recognize a spatial epitope or a molecular pattern rather than a classical continuous sequence. In addition, we have not found any increase in the binding of natural antibodies when GalNAcα residues were clustered. These results may help in further development of anticancer vaccines based on synthetic Tn constructs.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-Glycan antibodies; Cancer; Glycans; Natural antibodies; Tn antigen

Year:  2020        PMID: 32087569     DOI: 10.1016/j.molimm.2020.02.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

Review 1.  40 years of glyco-polyacrylamide in glycobiology.

Authors:  Alexander Tuzikov; Alexander Chinarev; Nadezhda Shilova; Elena Gordeeva; Oxana Galanina; Tatyana Ovchinnikova; Marcel Schaefer; Nicolai Bovin
Journal:  Glycoconj J       Date:  2021-01-14       Impact factor: 2.916

Review 2.  Mucins as anti-cancer targets: perspectives of the glycobiologist.

Authors:  Inka Brockhausen; Jacob Melamed
Journal:  Glycoconj J       Date:  2021-03-11       Impact factor: 2.916

3.  Low Levels of Natural Anti-α-N-Acetylgalactosamine (Tn) Antibodies Are Associated With COVID-19.

Authors:  Adrien Breiman; Nathalie Ruvoën-Clouet; Marie Deleers; Tiffany Beauvais; Nicolas Jouand; Jézabel Rocher; Nicolai Bovin; Nathalie Labarrière; Hanane El Kenz; Jacques Le Pendu
Journal:  Front Microbiol       Date:  2021-02-11       Impact factor: 5.640

Review 4.  Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer.

Authors:  Eugeniy P Smorodin
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

Review 5.  Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.

Authors:  Barbora Knoppova; Colin Reily; R Glenn King; Bruce A Julian; Jan Novak; Todd J Green
Journal:  J Clin Med       Date:  2021-09-29       Impact factor: 4.241

6.  Characterization of Structure and Antioxidant Activity of Polysaccharides From Sesame Seed Hull.

Authors:  Run-Yang Zhang; Jing-Hao Gao; Yi-Lin Shi; Yi-Fei Lan; Hua-Min Liu; Wen-Xue Zhu; Xue-De Wang
Journal:  Front Nutr       Date:  2022-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.